Characteristics | Adalimumab, n = 25 | Placebo, n = 24 |
---|---|---|
Age, yrs | 39.9 ± 10.8 | 35.1 ± 7.8 |
Male | 15 (60) | 10 (42) |
BMI | 25.0 ± 4.2 | 24.4 ± 3.7 |
Symptom duration, yrs | 13.8 ± 13.4 | 10.4 ± 7.1 |
Time since diagnosis, yrs | 4.6 ± 10.2 | 2.3 ± 3.5 |
Positive for HLA-B27 | 17 (68) | 19 (79) |
Previous disorders | ||
Psoriasis | 0 (0) | 2 (8) |
IBD | 1 (4) | 2 (8) |
Uveitis | 3 (12) | 7 (29) |
Radiographic AS1 | 13 (52) | 15 (63) |
hsCRP, median (range) | 4.2 (≤ 0.3–38) | 3.2 (≤ 0.3–74) |
BASDAI | 6.3 (1.2) | 6.4 (1.5) |
BASFI | 5.2 (1.9) | 5.0 (2.1) |
BASMI | 2.6 (2.0) | 2.8 (2.0) |
ASDAS | 3.5 (0.7) | 3.5 (0.9) |
Pain score | 68 (19) | 65 (19) |
PtGA | 70 (18.1) | 68 (18.9) |
PGA | 58 (22) | 62 (23) |
SPARCC MRI Spine Inflammation Index | 13.3 (17) | 10.7 (16) |
SPARCC MRI SIJ Inflammation Index | 7.7 (9.2) | 11.1 (14) |
mSASSS, median (range) | 2 (0–61) | 0 (0–53) |
↵1 Fulfill radiographic part of the modified New York criteria for AS. AS: ankylosing spondylitis; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; BASMI: Bath Ankylosing Spondylitis Metrology Index; ASDAS: Ankylosing Spondylitis Disease Activity Score; BMI: body mass index; IBD: inflammatory bowel disease; hsCRP: high-sensitivity C-reactive protein; mSASSS: modified Stoke Ankylosing Spondylitis Spine Score; PtGA: patient’s global assessment; PGA: physician’s global assessment; SPARCC: Spondyloarthritis Research Consortium of Canada; MRI: magnetic resonance imaging; SIJ: sacroiliac joints.